Amgen Announces Etelcalcetide Met Primary Endpoint of Non-Inferiority vs Cinacalcet
November 07, 2015 at 17:20 PM EST
Amgen (NASDAQ: AMGN) today presented the findings from a head-to-head Phase 3 study comparing intravenous etelcalcetide (AMG 416) with ...